Open AccessVirologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
Author(s) -
Isabelle Pellegrin,
Dominique Breilh,
François Montestruc,
Anne Caumont,
Isabelle Garrigue,
Philippe Morlat,
C. Le Camus,
Marie-Claude Saux,
Hervé Fleury,
JeanLuc Pellegrin
Publication year - 2002
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200207050-00004
Subject(s) - cmin , nelfinavir , cmax , pharmacokinetics , protease inhibitor (pharmacology) , resistance mutation , regimen , medicine , population , viral load , protease , pharmacology , virology , biology , immunology , virus , reverse transcriptase , antiretroviral therapy , gene , polymerase chain reaction , genetics , biochemistry , environmental health , enzyme
To assess the impact of HIV-1 protease and reverse transcriptase (RT) mutations, and pharmacokinetic parameters on virological responses to nelfinavir (NFV)-containing highly active antiretroviral therapy.